Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data from more than 600 individuals.

The New Playbook for Ditching Dangerous Senior Meds A new tool presented at the American Geriatrics Society (AGS) 2025 Annual Scientific Meeting may give clinicians practical and safer alternatives to risky medications for patients.

International Research in Cardiology 2010-2014 Dear colleagues!
The Cardioprogress Foundation presents the book «International Research in Cardiology», which includes the results of the most important international clinical trials presented in 2010-2024. The authors systematized studies in 21 sections, which include risk factors, antiplatelet and anticoagulant therapy, laboratory and instrumental diagnostics, arrhythmia, invasive cardiology, valvular heart diseases, intensive care in cardiology and more.

New Drug Combos Could Cut Heart Failure Mortality by 60% Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual German Society of Cardiovascular Medicine Annual Conference.

Dedicated to eternal memory Dear colleagues!
On these holidays, the Cardioprogress Foundation remembers the heroes of the Great Patriotic War, whose feat was immortalized in the hearts of their descendants.

Spanish Cardiologists Release Gender-Specific CV Guide The Spanish Society of Cardiology (SEC) Working Group on Women and Cardiovascular Diseases (SEC-GT CVD in Women) and the Association of Preventive Cardiology have convened an interdisciplinary group of experts from various Spanish societies and associations issued SEC-approved clinical guidelines published in the English-language edition of the Revista Española de Cardiología journal, which is designed to help medical professionals. in the diagnosis and treatment of cardiovascular diseases in women, paying special attention to gender differences.

Risk Model Validates Finerenone Effect in Heart Failure The Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction (PREDICT-HFpEF) tool effectively stratified cardiovascular risk, with risk being higher in the highest than in the lowest score quintile. Finerenone was consistently effective across risk levels in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), with a large absolute benefit observed in high-risk patients.

Muslim fasting from a medical point of view Dear colleagues!
We offer you an article by Professor Mekhman N. Mamedov about medical aspects of muslim fasting and practical advice for applicants.

Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited. Bill is developing a new therapeutic approach targeting CXCR3 for the treatment of myocarditis with immunotherapy.

Ross Procedure Making a Comeback in Aortic Valve Disease The Ross procedure, which can be used to treat young people with severe aortic valve disease, has seen wide swings in popularity over the years, but now, with consistent data on long-term survival and valve durability, numbers are steadily climbing again.